ReviewMycoses2021
Proven Aspergillus flavus pulmonary aspergillosis in a COVID-19 patient: A case report and review of the literature.
Review in Mycoses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Pooled it
- Article
- Article
- Endocarditis caused by Aspergillus fumigatus in a patient 9 months after COVID-19 infection recovery: a case report and review of the literature.Journal of medical case reports · 2023Review
- Mucociliary transport deficiency and disease progression in Syrian hamsters with SARS-CoV-2 infection.JCI insight · 2023Article
- Genomic and Phenotypic Trait Variation of the Opportunistic Human Pathogen Aspergillus flavus and Its Close Relatives.Microbiology spectrum · 2022Article
- Comparative risk assessment of COVID-19 associated mucormycosis and aspergillosis: A systematic review.Health science reports · 2022Article
- An overview of COVID-19 related to fungal infections: what do we know after the first year of pandemic?Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Review
- Clinical and Imaging Features of COVID-19-Associated Pulmonary Aspergillosis.Diagnostics (Basel, Switzerland) · 2022Article
- Mucociliary Transport Deficiency and Disease Progression in Syrian Hamsters with SARS-CoV-2 Infection.bioRxiv : the preprint server for biology · 2022Article
- Invasive Fungal Infections Complicating COVID-19: A Narrative Review.Journal of fungi (Basel, Switzerland) · 2021Review
- Proven Aspergillus flavus pulmonary aspergillosis in a COVID-19 patient: A case report and review of the literature.Mycoses · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe COVID-19 patients complicated with aspergillosis are increasingly reported. We present a histopathological proven case of fatal COVID-19-associated pulmonary aspergillosis (CAPA), due to Aspergillus flavus. This report and existing published literature indicate diagnostic challenges and poor outcomes of CAPA in ICU patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.